Enterprise AI is entering a more cost-conscious phase as inference spending rises. Business leaders are weighing where models run, which ones they use and how much data they are prepared to entrust to third parties, and those choices are reshaping purchasing decisions.
Pathos AI, which is developing cancer drugs, has raised $237 million at a $3 billion valuation. Bristol Myers Squibb led the Series E round, and the startup's backers include AstraZeneca, NEA and General Atlantic.
This episode of the 404 Media podcast covers the latest wave of AI slop, a major AI shake-up at Accenture and the bankruptcy of Character.ai, along with how people are stripping surveillance ads from their TVs.
Analysts argue that fears of AI agents upending the banking industry are exaggerated, at least for the moment.
Depending on the investor, AI looks either like a huge opportunity or an increasingly risky bet, given heavy infrastructure spending and growing public hostility to data centers. The column argues both views hold, as large venture investments in AI continued this week.
Anthropic published a report saying it is hiring fewer junior technical staff and that human attention has become the main bottleneck as it leans more on its Claude agents. Some experts are sceptical, noting that earlier predictions by its CEO Dario Amodei about jobs and AI-written code did not materialise.